



SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company" or the "Group")

Independent Investigation Appointment

20 February 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that it has appointed its new Non-Executive Director and Chair of the Audit Committee, Alyson Levett, to oversee the continuing investigation process on behalf of the Board. It has also appointed FRP Advisory to undertake an independent, forensic review into the matters outlined by the Company on Monday, 16 February. Existing external legal and professional advisers will also support the process, as necessary.

Alyson Levett, Non-Executive Director and Chair of the Audit Committee of SkinBioTherapeutics, said: *"The Board's aim has always been to act quickly - undertaking an investigation whilst maintaining business continuity and minimising disruption. FRP Advisory can help us expedite our investigation and enable us to issue the HY results as soon as possible in the confidence that all issues have been identified. The senior leadership team can then return their focus to running and growing the business."*

The Company will continue to provide updates as appropriate.

-Ends-

For more information please contact:

SkinBioTherapeutics plc
Martin Hunt, Executive Chairman
Emily Bertram, CFO

ir@skinbiotix.com

Singer Capital Markets (Nominated Adviser & Broker)
Philip Davies
James Todd
Patrick Weaver

+44 (0) 020 7496 3000

Vigo Consulting
Melanie Toyne-Sewell, Rozi Morris

+44 (0) 20 7390 0230
SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix[®], is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix[®]) and food supplements that harness the gut-skin axis (AxisBiotix[™]). The cosmetic pillar has a partnership with Croda plc where SkinBiotix[®] is being used as an active skin ingredient with the Croda trade name, Zenakine[™]. The AxisBiotix[™] pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit:
www.SkinBioTherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCDBGDDDSBDGLC